bpc-157 regulatory status fda Understanding the Legal Risks of and Other Unapproved Peptides – Holt Law FDA Peptide Regulation and HHS

Food and Drug Administration has flagged BPC-157 among bulk substances reviewed for compounding, and long-term human safety has not been established

[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Gazzaniga, F., Stebbins, R., Chang, S

133111086.10.1016/j.biopha.2020.111086 (2021)

30 days (reconstituted) Mechanism Classification Primary Mechanism: NNMT (Nicotinamide N-methyltransferase) Inhibitor Target Enzyme: Nicotinamide N-methyltransferase Cellular Effect: Increases intracellular NAD+ and SAM levels Metabolic Pathway: NAD+ salvage pathway modulation Selectivity: Highly selective for NNMT (no cross-reactivity with related enzymes) Pharmacological Properties Route of Administration: Subcutaneous injection Bioavailability: High (subcutaneous)

Multiple paxillin binding sites regulate FAK function

General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data